Venetoclax and Azacitidine with Stem Cell Transplant for Acute Myeloid Leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of two drugs (venetoclax and azacitidine) followed by a stem cell transplant from a donor for patients with a specific type of acute myeloid leukemia (AML) that has low bone marrow cell count or has developed from a prior blood disorder. The goal is to control the disease and give you a chance at a cure through transplantation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Newly diagnosed AML (never treated before) with low bone marrow cellularity, prior blood disorder history, or radiation/chemotherapy-related changes
- Your doctor believes you are healthy enough to receive a stem cell transplant
- Adequate liver, kidney, and lung function
- A matched donor available for stem cell transplant
- No active serious infections, HIV, hepatitis, or uncontrolled heart disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
This trial tests the combination of venetoclax (a targeted pill) and azacitidine (a chemotherapy-like drug) as consolidation therapy after initial treatment in adults with high-risk acute myeloid leukemia (AML) who have achieved remission and are planning a stem cell transplant. The goal is to see if this combination helps prevent relapse before transplant.
This trial tests two cancer medicines—decitabine or azacitidine (also called “hypomethylating agents”) plus venetoclax—given after an allogeneic stem cell transplant to help prevent relapse in people with high-risk AML or MDS. If you have measurable remaining leukemia cells after transplant, this study may be especially relevant.
This trial tests a new combination of chemotherapy drugs before a stem cell transplant for people with acute myeloid leukemia (AML) in first remission who are not very fit or have other health problems. The goal is to make the transplant safer for these patients.
This trial tests whether giving Venetoclax and Azacitidine (VA) after your first remission helps keep you in remission before a stem cell transplant. It's for people with intermediate-risk AML who are planning to have a donor transplant.
This trial tests a combination of three drugs (tretinoin, azacitidine, and venetoclax) for people newly diagnosed with acute myeloid leukemia (AML) who have not yet received chemotherapy. The goal is to see if this combination can help control the leukemia.
Hear when a new Hypoplastic Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.